Articles

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia

Department of Internal Medicine III, University of Munich, Germany;German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Germany
German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Germany
Department of Internal Medicine III, University of Munich, Germany
Department of Internal Medicine III, University of Munich, Germany
Department of Internal Medicine III, University of Munich, Germany
Department of Internal Medicine III, University of Munich, Germany;German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Internal Medicine III, University of Munich, Germany;German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, Ludwig-Maximilians-Universität (LMU) München, Germany
Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, Ludwig-Maximilians-Universität (LMU) München, Germany
Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, Ludwig-Maximilians-Universität (LMU) München, Germany
German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Internal Medicine III, University of Munich, Germany
Department of Internal Medicine III, University of Munich, Germany
Institute of Biostatistics and Clinical Research, University of Münster, Germany
Institute of Biostatistics and Clinical Research, University of Münster, Germany
Department of Medicine, Hematology and Oncology, University of Münster, Germany
German Society of Hematology and Oncology, Berlin, Germany
Department of Internal Medicine III, University of Munich, Germany
Department of Internal Medicine III, University of Munich, Germany
Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany
Department of Internal Medicine III, University of Munich, Germany;German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Internal Medicine III, University of Munich, Germany;German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Germany
Department of Internal Medicine III, University of Munich, Germany;German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Vol. 103 No. 3 (2018): March, 2018 https://doi.org/10.3324/haematol.2017.178442